152 related articles for article (PubMed ID: 35249787)
1. Tobramycin safety and efficacy review article.
Schwarz C; Taccetti G; Burgel PR; Mulrennan S
Respir Med; 2022; 195():106778. PubMed ID: 35249787
[TBL] [Abstract][Full Text] [Related]
2. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
[TBL] [Abstract][Full Text] [Related]
3. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
4. Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
McKeage K
Drugs; 2013 Nov; 73(16):1815-27. PubMed ID: 24194436
[TBL] [Abstract][Full Text] [Related]
5. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
6. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.
Hamed K; Debonnett L
Ther Adv Respir Dis; 2017 May; 11(5):193-209. PubMed ID: 28470103
[TBL] [Abstract][Full Text] [Related]
7. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.
Panguluri S; Gunda P; Debonnett L; Hamed K
Clin Drug Investig; 2017 Aug; 37(8):795-805. PubMed ID: 28643178
[TBL] [Abstract][Full Text] [Related]
9. The use of tobramycin for Pseudomonas aeruginosa: a review.
Fiel SB; Roesch EA
Expert Rev Respir Med; 2022 May; 16(5):503-509. PubMed ID: 35320051
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
[TBL] [Abstract][Full Text] [Related]
11. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
Somayaji R; Parkins MD
Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
[TBL] [Abstract][Full Text] [Related]
12. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G
Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
[TBL] [Abstract][Full Text] [Related]
13. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
[TBL] [Abstract][Full Text] [Related]
15. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF).
Harrison MJ; McCarthy M; Fleming C; Hickey C; Shortt C; Eustace JA; Murphy DM; Plant BJ
J Cyst Fibros; 2014 Dec; 13(6):692-8. PubMed ID: 24815094
[TBL] [Abstract][Full Text] [Related]
16. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
Máiz L; Girón RM; Olveira C; Quintana E; Lamas A; Pastor D; Cantón R; Mensa J
Expert Opin Pharmacother; 2013 Jun; 14(9):1135-49. PubMed ID: 23586963
[TBL] [Abstract][Full Text] [Related]
17. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
18. Effect of Inspiratory Maneuvers on Lung Deposition of Tobramycin Inhalation Powder: A Modeling Study.
Meerburg JJ; Andrinopoulou ER; Bos AC; Shin H; van Straten M; Hamed K; Mastoridis P; Tiddens HAWM
J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):61-72. PubMed ID: 32073919
[No Abstract] [Full Text] [Related]
19. Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough.
Meerburg JJ; Albasri M; van der Wiel EC; Andrinopoulou ER; van der Eerden MM; Majoor CJ; Arets HGM; Heijerman HGM; Tiddens HAWM
Pediatr Pulmonol; 2019 Nov; 54(11):1794-1800. PubMed ID: 31393073
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
